MétaCan
Menu
Back to cohort

Use of 6-Mercapturine/Azathioprine as the Immunomodulator of Choice for Moderately Active Crohnʼs Disease

2005· letter· en· W4245713181 on OpenAlexaff
Anne M. Griffiths

Bibliographic record

VenueInflammatory Bowel Diseases · 2005
Typeletter
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsSickKids FoundationUniversity of Toronto
Fundersnot available
KeywordsAzathioprineCrohn's diseaseMedicineCrohn diseaseGastroenterologyInternal medicineDiseaseImmunology

Abstract

fetched live from OpenAlex

The efficacy of 6-mercaptopurine (6-MP) and its prodrug, azathioprine (AZA), in maintaining clinical remission in Crohn's disease has been clearly documented by metaanalyses1 of randomized controlled trial data accrued in adults. There is similar Level I evidence of efficacy for these immunomodulatory drugs as steroid-sparing agents in controlling intestinal inflammation in pediatric patients.2 Indeed, AZA/6-MP therapy has become a mainstay of the management of pediatric and adult Crohn's disease, a reflection of the increased body of evidence in support of both the therapeutic efficacy and safety profiles of these drugs. The subject of this debate, however, is whether AZA/6-MP should be included in the first-line therapy from the time of diagnosis in all patients presenting with “moderately active” Crohn's disease. The heterogeneity of the phenotypic expression of Crohn's disease and its variable natural history, considered in combination with the potential drug toxicities, do not support such a blanket recommendation. The best available evidence for this debate comes from the multicenter randomized controlled trial of Markowitz et al.2 Over the course of 7 years at 18 pediatric institutions, 55 children and adolescents newly recognized to have Crohn's disease of at least moderate severity were randomized to receive as first treatment either prednisone plus placebo or prednisone plus 6-MP. A comparison of the rates of clinical relapse over the subsequent 18 months supports the use of 6-MP to maintain remission and spare the use of steroids.2 Nevertheless, 50% of the children treated at diagnosis with a course of prednisone remained in continuous clinical remission at 12 months, and even at 18 months, without receiving any concomitant therapy.2 As otherwise stated, more than one-half of the children remaining in clinical remission during 6-MP therapy would have remained as well without receiving it. One-half of the young patients with moderately severe Crohn's disease at diagnosis were given an immunomodulatory drug unnecessarily. Moreover, the rates of linear growth, a very important outcome variable in assessing the efficacy of any therapy in children, seemed comparable in both the group treated with 6-MP and in the control (placebo-treated) group.2 The control of intestinal symptoms and the reduction in steroid usage achieved with 6-MP were not associated with improved growth.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.012
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0120.008
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.249
Teacher spread0.233 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2005
Admission routes1
Has abstractno

Explore more

Same venueInflammatory Bowel DiseasesSame topicInflammatory Bowel DiseaseFrench-language works237,207